ALS Worldwide recently launched a crowdfunding campaign to bring a very promising ALS/MND Drug called MicroNeurotrophins to a Phase 1 Clinical Trial in just 12 to 18 months! Please watch this video and visit http://igg.me/at/newALSmedication to donate, learn more and spread the word.
MicroNeurotrophins mimic the beneficial properties of neurotrophins--naturally occurring proteins that help motor neurons develop, grow, function, signal, and even repair themselves--but are small enough to pass through the blood brain barrier and reach motor neurons affected by ALS/MND.
To fast track this very promising drug, ALS Worldwide has organized The ALS MicroNeurotrophin Research Consortium, which includes Harvard University/Massachusetts General Hospital; Virginia Commonwealth University; Penn State Hershey; The University of Sheffield’s Institute for Translational Neuroscience (SITraN) UK and the University of Crete.
We know you want to contribute directly to research that will provide treatments to patients as soon as possible. That's why ALS Worldwide has launched a grassroots fundraising campaign to accelerate this critically important research.
100% of all donations go directly to the ALS MicroNeurotrophin Research Consortium.
$4.5 million dollars is needed to begin human clinical trials. ALS Worldwide has already raised $600,000. Our goal is to raise $1.4 million over the next 56 days through this crowdfunding campaign on Indiegogo.com. That’s one-third of what is needed. We will continue to pursue traditional philanthropy and institutional grants to reach our overall goal.
Together, we can transform the way scientific research is funded to speed up the process and give hope to ALS/MND patients and their loved ones now. Thank you.
ALS Worldwide is a nonprofit organization that advances groundbreaking research and brings guidance, compassion and hope to the global ALS/MND community.
We provide free personalized support to ALS/MND patients and their loved ones in more than 85 countries via videoconference, email, phone and in-person visits.
Get help now. Please contact Sarah Byer, Director of Outreach and Counseling at [email protected] or 1-608-630-0407.
ALS Worldwide accelerates scientific breakthroughs by fostering collaboration and innovation among leaders from all sectors of medical research. Funded solely through the generosity of our supporters, ALS Worldwide has a proven record of using resources in the most cost-effective ways possible.
In 2008, Stephen and Barbara Byer founded ALS Worldwide to honor the memory of their son Ben, who died that year from ALS/MND at the age of 37. In 2013, Stephen and Barbara's daughter, Sarah Byer, and her husband Barry Wein, whose grandfather also died from ALS/MND, joined the nonprofit organization to contribute their extensive professional expertise and personal experience. Today, each member of the nonprofit organization draws upon his or her firsthand knowledge of the disease to fulfill ALS Worldwide's unique mission.
At ALS Worldwide, we see the roadblocks on the path to finding a cure for ALS/MND, but look past them. We have pursued many promising treatments that ultimately failed, but history has shown us that being positive and persistent will ultimately make finding the cure for ALS/MND inevitable. That's why ALS Worldwide is committed to funding, facilitating and sharing the most promising ALS/MND research. We will not quit until ALS/MND is a thing of the past. Until then, ALS Worldwide is on a mission to spread hope and share this simple message--each of us has what it takes to be part of the solution--galvanizing progress toward a cure.
Scientists require collaborators with diverse research expertise, skills, and specializations to advance their discoveries. Yet, too often researchers work in isolation or in competition with one another without producing results. For this reason, ALS Worldwide regularly brings together top experts from all sectors of medical research to increase dialogue, encourage partnerships and accelerate the pace of discovery and innovation. We are passionate in our commitment to people affected by ALS/MND and actively seek out the best and the brightest--those known for their scientific excellence, collaborative approach, patient-centric focus and sense of urgency.